11555 Sorrento Valley Road
Suite 100
San Diego, CA 92121
United States
(858) 224-1000
https://www.organovo.com
Settore/i:
Settore:
Impiegati a tempo pieno: 18
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Keith E. Murphy | Company Secretary & Executive Chairman | 626,24k | N/D | 1972 |
Ms. Vaidehi Joshi | Director of Discovery Biology & Director | 91,4k | N/D | 1986 |
Mr. Thomas P. Hess CPA, MBA | President & CFO | N/D | N/D | 1964 |
Dr. Curtis M. Tyree Ph.D. | Senior Vice President of Strategy & Business Development | N/D | N/D | N/D |
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.
L'ISS Governance QualityScore di Organovo Holdings, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.